GoodRx
GoodRx is a digital healthcare platform that offers prescription drug price comparison, discount coupons, and telehealth services. The company works with pharmacy benefit managers to negotiate discounted prices at over 70,000 pharmacies, generating revenue through referral fees paid by PBMs when consumers use GoodRx discount codes.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
GoodRx launched as a straightforward prescription price comparison tool addressing real opacity in drug pricing. The founders, former Facebook executives, built a free service funded by angel investment with minimal enshittification vectors. Monetization was limited to basic PBM referral fees, and the company had no subscription layer, no health data advertising, and no regulatory issues.
Private equity investment from Francisco Partners, Spectrum Equity, and Silver Lake transformed GoodRx from a bootstrapped startup into a growth-oriented platform. The Gold subscription launched in May 2017, adding recurring revenue pressure. Most critically, GoodRx began embedding Facebook tracking pixels and SDKs on its platform in late 2017 to share user health data with advertisers while its privacy policy promised the opposite. The PBM referral fee model deepened GoodRx's role as a middleman profiting from pharmacy pricing opacity.
The 2020 IPO at a $12.7 billion valuation cemented the dual-class share structure giving co-founders 96.8% voting control. By this point, GoodRx had been sharing health data with Facebook, Google, and Criteo for three years while falsely claiming HIPAA compliance and promising never to share health information with advertisers. The HeyDoctor acquisition expanded telehealth data collection. Drug Channels exposed how GoodRx profited from pharmacy pricing opacity without negotiating directly with pharmacies.
The FTC's landmark enforcement action in February 2023 imposed a $1.5 million fine and a permanent ban on sharing health data for advertising, marking the first-ever case under the Health Breach Notification Rule. GoodRx had already laid off 16% of its workforce in August 2022 after a 39% stock crash. The Kroger pricing dispute exposed dangerous revenue concentration. Co-founders stepped down as co-CEOs in April 2023, and vitaCare was deprioritized during restructuring. The Integrated Savings Program launched, deepening PBM entanglement.
Three pharmacy price-fixing class action lawsuits and the NCPA's intervention have escalated legal exposure, with cases consolidated into a federal MDL. Monthly active consumers fell 14% year over year as the Rite Aid bankruptcy, pharmacy closures, and competition from Amazon Pharmacy and Cost Plus Drugs eroded the user base. The $25 million class action data settlement was rejected by a federal judge. GoodRx Gold's value proposition deteriorated further with the Gold Price Protection discontinuation, while the company launched a $450 million buyback program.
Alternatives
Nonprofit drug discount database that finds patient assistance programs, state pharmaceutical programs, and discount cards without monetizing your health data. Particularly useful for brand-name drugs where Cost Plus Drugs and discount cards provide less savings. Free to use with no account required.
Mark Cuban's online pharmacy sells generics at transparent cost + 15% markup with no PBM middleman and no health data advertising. Scores 12 (Healthy, improving) — directly addresses GoodRx's core problems. Easy switch for generic medications — search your drug, get the price, fill online with free delivery or at select pharmacies. Does not carry all medications and requires a valid prescription.
Free prescription savings card with no subscription required and no documented history of selling health data to advertisers — unlike GoodRx. Works at 35,000+ pharmacies. Easy switch — search your drug, show the card at the pharmacy. Prices are competitive with GoodRx and sometimes lower. Backed by RedCard, a pharmacy benefits company, rather than a PBM-referral model.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (32 events)
GoodRx Founded by Former Facebook Executives
Doug Hirsch (former VP of Product at Facebook), Trevor Bezdek, and Scott Marlette (one of Facebook's first 20 employees) founded GoodRx in Santa Monica, California. The platform was created to address prescription drug price opacity by aggregating discount prices across pharmacies.
GoodRx Launches Price Comparison with Opaque PBM Fee Structure
GoodRx launched its prescription drug price comparison tool with a database of over one million prices across 6,000+ medications. While the service provided consumer price transparency, the underlying PBM referral fee model was opaque from the start -- users could not see the $5-$10 transaction fees GoodRx collected from PBMs on each coupon use, or understand how the spread-pricing economics behind displayed prices worked.
Francisco Partners and Spectrum Equity Acquire Majority Stake
Private equity firms Francisco Partners and Spectrum Equity acquired a majority stake in GoodRx in a Series B round. The PE investment introduced institutional growth pressure and monetization expectations, shifting the company from a bootstrapped startup to a PE-backed growth vehicle.
GoodRx Gold Subscription Plan Launched
GoodRx launched its Gold subscription plan at $5.99/month (later $9.99/month), offering members deeper discounts than the free tier. The subscription added a recurring revenue stream alongside PBM referral fees, but would later face criticism for deceptive signup practices and prices that sometimes exceeded the free tier.
GoodRx Begins Sharing Health Data with Facebook via Tracking Pixels
Beginning in at least October 2017, GoodRx incorporated Facebook tracking pixels and SDKs on its website and app that shared users' prescription medication data, health conditions, and personal identifiers with Facebook, Google, and Criteo. This occurred while GoodRx's privacy policy promised it would 'never provide advertisers any information that reveals a personal health condition.'
Silver Lake Invests at $2.8 Billion Valuation
Silver Lake made a strategic growth investment in GoodRx, taking about a third of the company in equity at a $2.8 billion valuation. The investment joined existing PE backers Francisco Partners and Spectrum Equity, further concentrating private equity ownership and growth expectations ahead of a planned IPO.
Kroger Rx Savings Club Launched Powered by GoodRx
GoodRx partnered with Kroger to launch the Kroger Rx Savings Club, a white-label prescription discount program powered by GoodRx technology. Kroger accounted for less than 5% of pharmacies in GoodRx's network but generated nearly one-quarter of prescription transaction revenue, creating a dangerous concentration of revenue dependency.
GoodRx Uploads User Medication Data to Facebook for Ad Targeting
In August 2019, GoodRx compiled lists of users who had purchased specific medications including heart disease and blood pressure drugs, uploading their email addresses, phone numbers, and mobile advertising IDs to Facebook for targeted advertising campaigns. This was among the most egregious instances of health data monetization documented by the FTC.
GoodRx Acquires Telehealth Company HeyDoctor
GoodRx acquired HeyDoctor, a telemedicine company, and rebranded it as GoodRx Care. The acquisition expanded GoodRx beyond prescription discounts into virtual healthcare visits, adding a telehealth revenue stream but also expanding the surface area for health data collection and monetization.
Drug Channels Exposes How GoodRx Profits from Broken Pricing System
Drug Channels published an analysis showing how GoodRx profits from the opaque PBM spread-pricing system without negotiating directly with pharmacies. GoodRx collects referral fees from PBMs each time a consumer uses a discount code, effectively profiting as a middleman in a system that already squeezes independent pharmacies on reimbursement rates.
GoodRx IPO Raises $1.1 Billion at $12.7 Billion Valuation
GoodRx went public on the NASDAQ at $33 per share, above the expected $24-$28 range, raising over $1.1 billion at a valuation of approximately $12.7 billion. The dual-class share structure gave co-founders Hirsch and Bezdek approximately 96.8% of total voting power through Class B shares carrying 10 votes each, insulating them from shareholder accountability.
Amazon Pharmacy Launch Threatens GoodRx's Core Business
Amazon launched Amazon Pharmacy with Prime member discounts, directly competing with GoodRx for uninsured and underinsured consumers. GoodRx stock dropped over 20% on the news. Amazon's entry marked the first serious competitive threat from a major tech company to GoodRx's discount card model.
GoodRx Acquires HealthiNation for $75 Million
GoodRx acquired HealthiNation, a health video content producer, for $75 million in cash. The acquisition provided pharmaceutical manufacturers new ways to reach audiences through health content, expanding the pharma manufacturer solutions revenue stream and deepening the advertising monetization model.
GoodRx Stock Crashes 39% on Weak Revenue Forecast
GoodRx shares plunged 39% after the company reported Q4 2021 revenue of $213.3 million but gave guidance for 2022 growth of only 23%, well below analyst expectations of $963 million. The stock price collapse from its IPO high of over $60 to under $15 destroyed shareholder value and signaled fundamental business model concerns.
GoodRx Acquires vitaCare for $150 Million
GoodRx completed the acquisition of vitaCare Prescription Services for $150 million from TherapeuticsMD. vitaCare's tech platform helped patients navigate brand medication access and adherence, expanding GoodRx's pharma manufacturer solutions offerings. The business was later deprioritized during the 2023 restructuring.
Kroger Stops Accepting GoodRx Discounts in Pricing Dispute
Kroger suspended acceptance of GoodRx discount codes across its pharmacy network in a dispute over spread pricing margins. GoodRx disclosed that Kroger accounted for nearly one-quarter of its prescription transaction revenue despite representing less than 5% of network pharmacies. Consumers lost access to GoodRx discounts at all Kroger pharmacies simultaneously, and the company blamed the dispute for a 5% decrease in monthly active users from 6.4 million to 6.1 million.
GoodRx Lays Off 140 Employees, 16% of Workforce
GoodRx laid off approximately 140 employees, representing 16% of its workforce, primarily in technology and marketing groups. The company expected $23-$25 million in annualized cash savings. Glassdoor reviews described the layoff process as poorly handled, with employees learning of termination in a Zoom meeting where cameras, microphones, and chat were disabled.
FTC Imposes $1.5 Million Fine for Health Data Sharing Violations
The FTC announced its first-ever enforcement action under the Health Breach Notification Rule against GoodRx, imposing a $1.5 million civil penalty. The FTC found GoodRx shared sensitive health information including prescription medications, health conditions, and personal identifiers with Facebook, Google, and Criteo for advertising since at least 2017, while falsely displaying a HIPAA compliance seal. GoodRx was permanently barred from sharing health data for advertising and placed under 20 years of government scrutiny.
Co-Founders Step Down as Co-CEOs
Trevor Bezdek and Doug Hirsch stepped down as co-CEOs of GoodRx. Scott Wagner, former GoDaddy CEO, was appointed as interim CEO. Bezdek became chairman of the board while Hirsch took on the role of chief mission officer. Co-founder Scott Marlette also departed the board in 2023, marking a significant transition from founder-led operations.
Judge Approves FTC Settlement with 20-Year Oversight
A federal judge approved the FTC's $1.5 million settlement with GoodRx, formalizing the permanent ban on sharing health data for advertising and establishing 20 years of government oversight. The settlement required GoodRx to obtain affirmative express consent before disclosing health information to any third party and to implement a comprehensive privacy program.
GoodRx and MedImpact Launch Integrated Savings Program
GoodRx partnered with PBM MedImpact to launch an integrated savings program for generic medications, where GoodRx's proprietary pricing data is embedded in PBM systems to automatically compare and apply the lowest price. Independent pharmacies later alleged this program enabled PBMs to suppress reimbursement rates using competitively sensitive data shared by GoodRx.
Rite Aid Bankruptcy Impacts GoodRx Pharmacy Network
Rite Aid filed for Chapter 11 bankruptcy protection in October 2023, beginning a wave of store closures that eventually eliminated all 2,300+ locations. GoodRx attributed a $35-$40 million annual revenue impact to the Rite Aid bankruptcy, reducing prescription transaction volume and shrinking GoodRx's pharmacy network coverage.
GoodRx Repurchases $77.8 Million in Stock During Q4 2023
GoodRx repurchased $77.8 million worth of Class A common stock (approximately 14.1 million shares) during Q4 2023 under its share repurchase program. This represented a significant capital allocation to buybacks while the company posted a net loss for full year 2023, prioritizing stock price support over reinvestment.
GoodRx Board Approves $450 Million Stock Buyback Program
GoodRx's board of directors authorized a new $450 million stock repurchase program with no expiration date. The program authorized share repurchases at management's discretion, representing a significant shareholder extraction mechanism for a company that had only recently achieved modest profitability.
GoodRx Shifts to Direct Pharmacy Contracting Model
GoodRx began contracting directly with key retail pharmacy partners on a subset of drugs, creating a hybrid model alongside its traditional multi-PBM network. This direct contracting approach deepened pharmacy network dependencies and introduced mild switching friction, as consumers using GoodRx's directly contracted prices at specific pharmacies could not easily replicate those savings through competing discount card services.
Judge Keeps Meta and Google in GoodRx Data Sharing Lawsuit
A federal judge refused to dismiss Meta and Google from the class action lawsuit over GoodRx's unauthorized health data sharing, ruling that the tech companies could be held liable as co-conspirators in the unauthorized disclosure of consumer health information used for advertising purposes.
Independent Pharmacies File First Price-Fixing Lawsuit Against GoodRx
Independent pharmacies filed the first of three class action lawsuits against GoodRx and major PBMs (CVS Caremark, Express Scripts, MedImpact, Navitus) alleging the Integrated Savings Program constitutes illegal price fixing. The lawsuits claim GoodRx aggregates competitively sensitive PBM reimbursement data and distributes it so PBMs agree not to compete on pharmacy payments, potentially costing pharmacies $35 million in 2024 alone.
GoodRx Appoints Wendy Barnes as CEO, Ending Interim Leadership
GoodRx appointed healthcare industry veteran Wendy Barnes as president and CEO effective January 1, 2025, replacing interim CEO Scott Wagner. Barnes previously served as CEO of RxBenefits and held leadership roles at Express Scripts, Rite Aid, and Pfizer. Her PBM industry background raised questions about whether she would reform or deepen GoodRx's PBM-dependent business model.
NCPA Joins Price-Fixing Class Action Against GoodRx
The National Community Pharmacists Association (NCPA), representing over 19,000 independent pharmacies, joined the class action lawsuit against GoodRx and PBMs. NCPA CEO B. Douglas Hoey stated that GoodRx's model 'preferentially lists some large chain pharmacies in their search results despite the higher-ranked pharmacies having higher prices, excluding nearly all independent pharmacies from appearing in the results.'
Price-Fixing Cases Consolidated into MDL in Rhode Island
The Judicial Panel on Multidistrict Litigation consolidated all GoodRx pharmacy price-fixing lawsuits into MDL No. 3148 in the District of Rhode Island, titled In Re: GoodRx and Pharmacy Benefit Manager Antitrust Litigation (No. II). The consolidation signaled the growing scale and seriousness of the antitrust allegations.
GoodRx Proposes $25 Million Class Action Data Sharing Settlement
GoodRx proposed a $25 million settlement to resolve class action claims over unauthorized health data sharing with Facebook, Google, and Criteo between 2017 and 2020. However, Judge Martinez-Olguin rejected both the initial $25 million proposal and a revised $32 million settlement in January 2026, finding the parties had 'largely failed to address the Court's previously-identified concerns.'
GoodRx Gold Price Protection Feature Discontinued
GoodRx discontinued its Gold Price Protection feature effective December 31, 2025, eliminating a key benefit that guaranteed Gold members would pay the lower of the GoodRx Gold price or the free GoodRx price. The discontinuation further eroded the value proposition of the $9.99/month Gold subscription, contributing to declining subscriber numbers.
Evidence (35 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (4 entries)
Added 1 missing dimension narrative